CD4 and neoplasm: Since administration of the triple combination (WKYMVm+5-FU+mDCs) elicited potent anti-tumor activity against the heterotopic cancer animal model, we examined what types of cells are recruited into the tumor by immunohistochemistry using anti-CD3, anti-CD4, anti-CD8, anti-CD11b, or anti-DX5 antibody.